Enlivex has announced powerful results for a Phase II treatment of Covid

Israeli immunotherapy company Enlivex Therapeutics (Nasdaq: ENLV) has reported strong results in its Phase 2 trial of the effectiveness of its drug, Alloctera, in patients in severe or critical condition of Covid-19. The trial involved 16 patients without a control group, of whom nine were severely ill with Covid-19 and seven were in critical condition. Twenty-eight days after providing treatment for the first time to 16 patients, there were no deaths, and 14 of the 16 patients were discharged from hospital and returned home. Two of the patients are still in the hospital on ventilators in the intensive care unit. On average, patients were discharged from the hospital 5.3 days after starting treatment with Alloctera. RELATED ARTICLES Enlivex points to more success in the Covid-19 trial, as Enlivex ramps up in Covid-19 success – raising questions Enlivex is raising $ 5.3 million on Nasdaq, and merging with Bioblast. It is difficult to evaluate the data because it is impossible to know the patient profile and how they were selected. However, the data is encouraging and consistent with the five other patients in a Phase 1 trial where all five patients were released from hospital. Enlivex will send these results to regulatory authorities in the United States, Europe, and other countries to find out what additional trials are needed to prove its effectiveness in patients. Enlivex’s share price rose 6.97% on the Nasdaq yesterday after results were announced, to $ 13.96, giving a market value of $ 188 million. The President of Enlivex is Shai Novick and the CEO is Oren Hershkovitz. Hershkowitz said: “We are pleased with the top results of this phase II clinical trial. We believe Allocetra, if approved, could cover the void that currently exists for treating dangerous and critical Covid-19 patients. Various surveys have shown that 25-32% of the population in the United States and major European countries are unwilling to get vaccinated, and concerns surrounding different mutant strains of the SARS-CoV-2 virus, our business model estimates the continuing demand for treating acute and critical Covid-19 patients. For years to come. ” Posted by Globes, Israel business news – en.globes.co.il – February 4, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021